Wei Meng

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    Wei Meng
    Drug Safety Evaluation and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    J Med Chem 51:1145-9. 2008
  2. ncbi Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors
    Wei Meng
    Departments of Discovery Chemistry, Bristol Myers Squibb, Research and Development, Princeton, New Jersey 08543 5400, USA
    J Med Chem 53:5620-8. 2010
  3. ncbi Synthesis of potent and highly selective inhibitors of human tryptase
    William A Slusarchyk
    The Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 12:3235-8. 2002
  4. ncbi Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase
    Gregory S Bisacchi
    The Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 14:2227-31. 2004
  5. ncbi Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
    Robert P Brigance
    Department of Discovery Chemistry, Bristol Myers Squibb, Research and Development, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 20:4395-8. 2010
  6. ncbi Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
    Bruce A Ellsworth
    Research and Development, Bristol Myers Squibb Co, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 18:4770-3. 2008
  7. ncbi Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors
    Stephen P O'Connor
    Department of Discovery Chemistry, Bristol Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 20:6273-6. 2010
  8. ncbi Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    Songping Han
    Metabolic Diseases Biology, Bristol Myers Squibb Research and Development, Princeton, New Jersey, USA
    Diabetes 57:1723-9. 2008
  9. ncbi Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors
    James C Sutton
    The Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 12:3229-33. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
    Wei Meng
    Drug Safety Evaluation and Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543, USA
    J Med Chem 51:1145-9. 2008
    ..These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes...
  2. ncbi Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors
    Wei Meng
    Departments of Discovery Chemistry, Bristol Myers Squibb, Research and Development, Princeton, New Jersey 08543 5400, USA
    J Med Chem 53:5620-8. 2010
    ....
  3. ncbi Synthesis of potent and highly selective inhibitors of human tryptase
    William A Slusarchyk
    The Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 12:3235-8. 2002
    ..7 nM) with high selectivity (>3000-fold) for tryptase versus related serine proteases including trypsin...
  4. ncbi Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase
    Gregory S Bisacchi
    The Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 14:2227-31. 2004
    ..In particular, BMS-354326 (4) is a highly potent tryptase inhibitor (IC(50)=1.8 nM), which has excellent selectivity against trypsin and most other related serine proteases...
  5. ncbi Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
    Robert P Brigance
    Department of Discovery Chemistry, Bristol Myers Squibb, Research and Development, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 20:4395-8. 2010
    ..SAR evaluation for these scaffolds was described as they may represent potential treatments for type 2 diabetes...
  6. ncbi Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
    Bruce A Ellsworth
    Research and Development, Bristol Myers Squibb Co, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 18:4770-3. 2008
    ..The lead C-arylglucoside (7a) demonstrates superior metabolic stability to its O-arylglucoside counterpart (4) and it promotes glucosuria when administered in vivo...
  7. ncbi Synthesis, SAR, and atropisomerism of imidazolopyrimidine DPP4 inhibitors
    Stephen P O'Connor
    Department of Discovery Chemistry, Bristol Myers Squibb Research and Development, PO Box 5400, Princeton, NJ 08543 5400, USA
    Bioorg Med Chem Lett 20:6273-6. 2010
    ..The effects of substituent pattern and type as well as stereochemical effects on inhibitor potency are discussed...
  8. ncbi Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    Songping Han
    Metabolic Diseases Biology, Bristol Myers Squibb Research and Development, Princeton, New Jersey, USA
    Diabetes 57:1723-9. 2008
    ..We have identified dapagliflozin as a potent and selective inhibitor of the renal sodium-glucose cotransporter SGLT2 in vitro and characterized its in vitro and in vivo pharmacology...
  9. ncbi Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors
    James C Sutton
    The Bristol Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543 4000, USA
    Bioorg Med Chem Lett 12:3229-33. 2002
    ....